论文部分内容阅读
目的观察依达拉奉注射液治疗急性脑梗死(ACI)的临床有效性和安全性。方法采用随机对照试验,选择确诊的ACI患者72例,随机分为依达拉奉治疗组(36例)及对照组(36例)。治疗组给予依拉奉注射液30mg静滴,2次/d,共14 d,同时给予血塞通0.4g静滴,阿司匹林作为基础治疗;对照组除不用依达拉奉外余均同治疗组。结果 2周后,2组NIHSS评分均有所改善,但治疗组疗效明显优于对照组(P<0.05),无明显不良反应。结论依达到奉治疗ACI安全有效,能明显改善临床症状,降低致残率。
Objective To observe the clinical efficacy and safety of edaravone injection in the treatment of acute cerebral infarction (ACI). Methods A randomized controlled trial was conducted in which 72 patients with ACI were selected and randomly divided into edaravone treatment group (36 cases) and control group (36 cases). The treatment group was treated with intravenous injection of 30mg IVR, 2 times / d for 14 days. Simvastatin 0.4g was given intravenously as the basic treatment. The control group was treated with edaravone, . Results After 2 weeks, the NIHSS scores of both groups were improved, but the treatment group was significantly better than the control group (P <0.05), no significant adverse reactions. Conclusion According to the treatment of ACI Feng safe and effective, can significantly improve the clinical symptoms and reduce the morbidity.